Cardiotoxicity Monitoring in Patients with Breast Cancer: Still a Major Challenge
Isr Med Assoc J
.
2020 Sep;22(9):576-577.
Authors
Dan Gilon
1
2
3
4
,
Zaza Iakobishvili
5
6
7
Affiliations
1
Department of Cardiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
2
Faculty of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
3
Department of Cardiology, Shamir Medical Center (Assaf Harofeh), Zerifin, Israel.
4
Maccabi Health Services, Cardio-Oncology Clinic, Rishon LeZion, Israel.
5
Department of Community Cardiology, Tel Aviv Jaffa District, Clalit Health Services, Tel Aviv, Israel.
6
Department of Cardiology, Assuta Ashdod Medical Center, Ashdod, Israel.
7
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
PMID:
33236557
No abstract available
Publication types
Editorial
MeSH terms
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / therapeutic use
Breast Neoplasms / drug therapy*
Cardiotoxicity / diagnosis*
Cardiotoxicity / etiology*
Female
Humans
Substances
Antineoplastic Agents